위장약 시장 : 약효 분류, 질병 유형, 투여 경로, 최종 사용자별 - 세계 예측(2025-2030년)

The Gastrointestinal Drugs Market was valued at USD 54.18 billion in 2023, expected to reach USD 57.27 billion in 2024, and is projected to grow at a CAGR of 5.78%, to USD 80.31 billion by 2030.

The scope of the gastrointestinal drugs market involves a broad focus on medications designed to treat a variety of digestive issues ranging from ulcers, inflammatory bowel disease, irritable bowel syndrome, to gastroesophageal reflux disease. This market is defined by the necessity of these medications to manage symptoms and improve the quality of life for millions of individuals worldwide. Application spans across prescriptions and over-the-counter medications used in hospitals, clinics, and homecare settings, with the end-use scope extending to both adult and pediatric populations. Market insights reveal a significant growth trajectory fueled by rising incidences of gastrointestinal disorders, increasing geriatric populations, and advancements in drug formulations. However, challenges such as stringent regulatory requirements, high costs of drug development, and potential side effects pose significant impediments to market expansion. Moreover, the COVID-19 pandemic has shifted priorities in healthcare allocations, impacting focus and funding toward non-urgent treatments. Opportunities abound in the development of biologics and biosimilars, personalized medicine approaches, and novel drug delivery systems like nanotechnology, which are expected to cater to unmet needs in treatment efficacy and patient compliance. To capitalize on these opportunities, companies should invest in R&D, focusing on innovative solutions that combine efficacy with minimal adverse reactions. They should also consider forging strategic alliances and collaborations to enhance their product pipeline and market reach. However, market players should remain cognizant of the competitive landscape characterized by high rivalry and the fast pace of technological evolution. The best areas for innovation and research include exploration into microbiome therapeutics and AI-driven patient stratification tools, allowing for tailored treatment plans. The nature of the gastrointestinal drugs market is dynamic, demanding continual innovation to address emerging challenges while maximizing therapeutic value and accessibility for patients globally.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gastrointestinal Drugs Market

The Gastrointestinal Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing geriatric population, changing lifestyles and eating habits
  • Development in biologics and a rising number of rectal related diseases
  • Drug development and rising awareness
• Market Restraints
  • Side effects associated with the drugs
• Market Opportunities
  • R&D activities to enhance drug development
  • Technological advancements in the treatment process
• Market Challenges
  • Unavailable permanent cure for diseases such as inflammatory bowel disease and Irritable bowel syndrome

Porter's Five Forces: A Strategic Tool for Navigating the Gastrointestinal Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gastrointestinal Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gastrointestinal Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gastrointestinal Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gastrointestinal Drugs Market

A detailed market share analysis in the Gastrointestinal Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gastrointestinal Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gastrointestinal Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gastrointestinal Drugs Market

A strategic analysis of the Gastrointestinal Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gastrointestinal Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bayer AG, Boehringer Ingelheim GmbH, Eisai Co., Ltd., Eli Lilly & Co., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Novo Nordisk A/S, Sanofi S.A., SFJ Pharmaceuticals Group, SRS Life Sciences Pte. Ltd., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Limited, and ZERIA Pharmaceutical Co.,Ltd..

Market Segmentation & Coverage

This research report categorizes the Gastrointestinal Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Category, market is studied across Acid Neutralizers, Anti-Inflammatory, Antiemetic & Antinauseants, Biologics, and Laxatives & Anti-diarrheal.
• Based on Disease Type, market is studied across Gastroesophageal Reflux Disorder and Irritable Bowel Syndrome.
• Based on Route of Administration, market is studied across Oral, Parenteral, and Rectal.
• Based on End User, market is studied across Hospital Pharmacies and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing geriatric population, changing lifestyles and eating habits
    • 5.1.1.2. Development in biologics and a rising number of rectal related diseases
    • 5.1.1.3. Drug development and rising awareness
  • 5.1.2. Restraints
    • 5.1.2.1. Side effects associated with the drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. R&D activities to enhance drug development
    • 5.1.3.2. Technological advancements in the treatment process
  • 5.1.4. Challenges
    • 5.1.4.1. Unavailable permanent cure for diseases such as inflammatory bowel disease and Irritable bowel syndrome
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Gastrointestinal Drugs Market, by Drug Category

• 6.1. Introduction
• 6.2. Acid Neutralizers
• 6.3. Anti-Inflammatory
• 6.4. Antiemetic & Antinauseants
• 6.5. Biologics
• 6.6. Laxatives & Anti-diarrheal

7. Gastrointestinal Drugs Market, by Disease Type

• 7.1. Introduction
• 7.2. Gastroesophageal Reflux Disorder
• 7.3. Irritable Bowel Syndrome

8. Gastrointestinal Drugs Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral
• 8.4. Rectal

9. Gastrointestinal Drugs Market, by End User

• 9.1. Introduction
• 9.2. Hospital Pharmacies
• 9.3. Retail Pharmacies

10. Americas Gastrointestinal Drugs Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Gastrointestinal Drugs Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Gastrointestinal Drugs Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Bayer AG
• 3. Boehringer Ingelheim GmbH
• 4. Eisai Co., Ltd.
• 5. Eli Lilly & Co.
• 6. GlaxoSmithKline PLC
• 7. Johnson & Johnson Services, Inc.
• 8. Novo Nordisk A/S
• 9. Sanofi S.A.
• 10. SFJ Pharmaceuticals Group
• 11. SRS Life Sciences Pte. Ltd.
• 12. Sun Pharmaceutical Industries Limited
• 13. Takeda Pharmaceutical Company Limited
• 14. Teva Pharmaceuticals Industries Limited
• 15. ZERIA Pharmaceutical Co.,Ltd.